CoChat

Matrix metalloproteinase inhibitor reversion‐inducing cysteine‐rich protein with Kazal motifs: A prognostic marker for good clinical outcome in human breast carcinoma

Open access
Span, Paul N., Sweep, C. G. J. (Fred), Manders, Peggy, Beex, Louk V. A. M., Leppert, David, Lindberg, Raija L. P. · 2003 · Cancer
Cited by 98

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

BACKGROUND: The recently described re version‐inducing c ysteine‐rich protein with K azal motifs (RECK) inhibits membrane Type 1 matrix metalloproteinase (MMP‐14), MMP‐2, and MMP‐9 secretion and enzymatic activity. Its expression is essential for normal vasculogenesis. Down‐regulation of RECK has been implicated in tumor angiogenesis and progression. METHODS: The authors assessed the prognostic value of RECK expression in tumor tissue specimens from 278 breast carcinoma patients with a median follow‐up time of 75 months (range, 2–169 months). RECK mRNA levels were measured by real‐time quantitative reverse transcriptase–polymerase chain reaction. RESULTS: Expression levels of RECK were lower in tumor tissue specimens than in adjacent normal breast tissue specimens from 10 patients (P = 0.028). No relevant associations of RECK with established clinicopathologic factors or treatment regimens were found. RECK expression predicted a longer recurrence‐free survival time (RFS; P = 0.037) at the optimal cutoff value (hazard ratio, 0.66; 95% confidence interval, 0.44–0.98). The 100 patients whose tumors exhibited low levels of RECK had a mean RFS time of 80.4 months and a 61.8% 5‐year RFS rate, whereas the 178 patients with tumors with high RECK expression had a mean RFS time of 91.2 months and a 73.0% 5‐year RFS rate. Multivariate Cox regression analysis showed that RECK expression maintained a significant independent prognostic value for RFS time (P = 0.047). CONCLUSIONS: These results are in agreement with the notion of RECK being an important tumor‐suppressor gene. Therefore, the possibility of applying RECK, a pharmaceutical mimetic, or drugs activating endogenous RECK expression, as possible therapeutic or preventive agents for breast carcinoma should be explored. Cancer 2003;97:2710–5. © 2003 American Cancer Society. DOI 10.1002/cncr.11395

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cncr.11395

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 98

Metadata

Authors
Span, P. N., Sweep, C. G. J. (., Manders, P., Beex, L. V. A. M., Leppert, D., & Lindberg, R. L. P.
Venue
Cancer
Publisher
Wiley
Published
2003-05-19
Volume
97
Issue
11
Pages
2710-2715
ISSN
  • 0008-543X (ISSN-L)
  • 1097-0142
OpenAlex
W1973018820
Cited by
98
References
2
FWCI
2.20
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Matrix metalloproteinase inhibitor reversion‐inducing cysteine‐rich protein with Kazal motifs: A prognostic marker for good clinical outcome in human breast carcinoma. https://app.cochat.ai/papers/10.1002/cncr.11395
The paper
Span, P. N., Sweep, C. G. J. (., Manders, P., Beex, L. V. A. M., Leppert, D., & Lindberg, R. L. P. (2003). Matrix metalloproteinase inhibitor reversion‐inducing cysteine‐rich protein with Kazal motifs: A prognostic marker for good clinical outcome in human breast carcinoma. Cancer. https://doi.org/10.1002/cncr.11395

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.